Phase 3 Clinical Study of AK112 for NSCLC Patients
A Randomized, Double-blind, Multi-center, Phase III Study of AK112 Combined With Pemetrexed and Carboplatin Versus Placebo Combined With Pemetrexed and Carboplatin in Patients With Locally Advanced or Metastatic EGFR-mutant Non-squamous NSCLC Who Have Failed Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKIs)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Lori Styles, MD
- Phone Number: 1-833-256-0522
- Email: medicalinformation@smmttx.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Sun Yat-sen University Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Ability to understand and voluntarily sign a written informed consent form (ICF), which must be signed before the specified study procedures required for the study are performed.
- Males or females aged ≥ 18 to ≤ 75 years at the time of signing informed consent.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.
- Life expectancy ≥3 months;
- Locally advanced (stage IIIB/IIIC) or metastatic (stage IV) non-squamous NSCLC confirmed by histology or cytology, inoperable and unable to receive radiotherapy and chemotherapy;
- The tumor histology, cytology or hematology confirmed the presence of EGFR activating mutations before enrollment
- Have previously received EGFR-TKI treatment and the treatment has failed
- Subjects have at least one measurable non-brain tumor lesion per RECIST v1.1
- Major organ function prior to treatment meets the following criteria
- Patients of childbearing potential must agree to use effective contraceptive measures
Exclusion Criteria:
- Histological or cytological pathology confirmed the presence of small cell carcinoma components, or the main component is squamous cell carcinoma
- There are reports confirming the existence of other driver gene mutations with known drug treatments
- Subjects who received any prior treatments targeting the mechanism of tumor immunity
- The subject has received systemic anti-tumor therapy other than EGFR-TKI
- Currently enrolled in any other clinical study
- Received EGFR-TKI treatment, palliative local treatment, non-specific immunomodulatory treatment within 2 weeks prior to the first dose; and Chinese herbal medicine or traditional Chinese medicinal products with anti-tumor indications within 1 weeks prior to the first dose.
- Tumor surrounds important blood vessels or has obvious necrosis, cavitation, or invades surrounding important organs and blood vessels.
- Symptomatic central nervous system metastases
- Active malignancies within the past 3 years, with the exception of tumors in this study and cured local tumors
- Active autoimmune disease requiring systemic treatment within 2 years prior to the start of study treatment
- There is a history of major diseases 1 year prior to the first dose.
- .Medical history of gastrointestinal perforation or gastrointestinal fistula within 6 months prior to the first dose
- Received chest radiation therapy prior to the first dose
- Presence of clinically symptomatic pleural effusion, pericardial effusion, or ascites requiring frequent drainage.
- Active or previously documented inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo in combination with Pemetrexed and Carboplatin
Subjects will receive Placebo Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles in treatment periods per the randomization schedule.
Afterward, Placebo Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
|
Subjects will receive Placebo Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles in treatment periods per the randomization schedule.
Afterward, Placebo Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
Other Names:
|
|
Experimental: Ivonescimab (SMT112 or AK112) in combination with Pemetrexed and Carboplatin
Subjects will receive Ivonescimab (SMT112 or AK112) Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles.
Afterward, AK112 Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
|
Subjects will receive Ivonescimab (SMT112 or AK112) Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles.
Afterward, Ivonescimab (SMT112 or AK112) Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression-free survival (PFS)
Time Frame: Up to 2 years
|
Progression-free survival (PFS) assessed by IRC per RECIST v1.1 in the ITT population.
|
Up to 2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
OS
Time Frame: Up to 2 years
|
Overall Survival (OS) in the ITT population
|
Up to 2 years
|
|
ORR
Time Frame: Up to 2 years
|
Efficacy measures such as overall response rate (ORR), which is the proportion of subjects with CR or PR by IRRC based on RECIST v1.1
|
Up to 2 years
|
|
DCR
Time Frame: Up to 2 years
|
Disease control rate (DCR), which is defined as the proportion of subjects with CR, PR, or SD, based on RECIST v1.1
|
Up to 2 years
|
|
DoR
Time Frame: Up to 2 years
|
Duration of response (DoR), which is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.
|
Up to 2 years
|
|
TTR
Time Frame: Up to 2 years
|
TTR is defined as the time to response base on RECIST v1.1
|
Up to 2 years
|
|
PFS
Time Frame: Up to 2 years
|
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first assessed by investigator Per RECIST 1.1.
|
Up to 2 years
|
|
AE
Time Frame: From the subject signs the ICF to 30 days (AE) and 90 days (SAE) after the last dose of study treatment or initiation of other anti-tumor therapy, whichever occurs first,up to 2 years
|
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), and clinically significant abnormal laboratory results.
|
From the subject signs the ICF to 30 days (AE) and 90 days (SAE) after the last dose of study treatment or initiation of other anti-tumor therapy, whichever occurs first,up to 2 years
|
|
Observed concentrations of AK112
Time Frame: through study completion, an average of 2 year
|
The endpoints for assessment of PK of AK112 include serum concentrations of AK112 at different timepoints after AK112 administration
|
through study completion, an average of 2 year
|
|
Number of subjects who develop detectable anti-drug antibodies (ADAs)
Time Frame: From first dose of AK112 through 90 days after last dose of AK112,up to 2 years
|
The immunogenicity of AK112 will be assessed by summarizing the number of subjects who develop detectable antidrug antibodies (ADAs)
|
From first dose of AK112 through 90 days after last dose of AK112,up to 2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Li Zhang, MD, Sun Yat-sen University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Amino Acids, Peptides, and Proteins
- Organic Chemicals
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Therapeutics
- Drug Administration Routes
- Drug Therapy
- Coordination Complexes
- Guanine
- Hypoxanthines
- Purinones
- Purines
- Glutamates
- Amino Acids, Acidic
- Amino Acids
- Amino Acids, Dicarboxylic
- Pemetrexed
- Carboplatin
- Injections
Other Study ID Numbers
Other Study ID Numbers
- AK112-301
- HARMONi-A (Other Identifier: Akeso)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.